Did You Know...
...that several people are credited with the invention of the flush toilet? Most people have heard of Thomas Crapper (1837-1910), the sanitary engineer who invented the valve-and-siphon arrangement that made the modern toilet possible. Another claimant to "the throne" was British inventor Alexander Cumming who patented a toilet in 1775. Then there's a nameless Minoan (a native of ancient Crete) who lived 4,000 years ago who supposedly was ahead of his time and created the first flush toilet!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7351570 | HDV nucleic acid molecules and applications thereof The invention concerns nucleic acid molecules derived from novel hepatitis D virus strains or isolates constituting genotypes different from known I, II and III genotypes, their fragments, corresponding proteins and their uses as diagnostic reagents. The invention a... | 04/01/2008 |
| 7306804 | HIV-specific T-cell induction This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression ... | 12/11/2007 |
| 7262270 | Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo The present invention provides a fusion protein construct (gp41HA) consisting of the ectodomain of the HIV-1IIIB envelope glycoprotein gp41 fused to a fragment of the influenza virus HA2 hemagglutinin protein. Immunization in-vivo via an intraperitoneal p... | 08/28/2007 |
| 7252827 | Conserved motif of hepatitis C virus E2/NS1 region Fusion proteins comprising an immunogenic polypeptide are disclosed. The immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SE... | 08/07/2007 |
| 7195768 | Polyvalent immunogen The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method. ... | 03/27/2007 |
| 7172761 | Polyvalent immunogen The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method. ... | 02/06/2007 |
| 7157089 | Immune responses using compositions containing stress proteins The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homolog... | 01/02/2007 |
| 7153509 | Immunogenic peptides comprising a T-helper epitope and a B-cell neutralizing antibody epitope The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method. ... | 12/26/2006 |
| 7141242 | Hepatitis B virus surface antigen mutant and methods of detection thereof The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at p... | 11/28/2006 |
| 7135185 | Conserved motif of hepatitis C virus E2/NS1 region Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-... | 11/14/2006 |
| 7135282 | Viral particles with exogenous internal epitopes The present invention relates to the expression of peptides on viral particles, and more particularly to the expression of peptides on the interior or the viral capsid. Methods are described for modifying viruses so that exogenous epitopes are expressed on the inter... | 11/14/2006 |
| 7129337 | Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes se... | 10/31/2006 |
| 7125957 | VPR mutant protein and its encoding gene having apoptosis-inducing action An apoptosis inducing agent which comprises a protein as being Vpr protein encoded by vpr gene of HIV-1 wherein 15 amino acid residues from the C-terminal are deleted, and an apoptosis inducing gene encoding said protein. The agent induces apoptosis of cells and the... | 10/24/2006 |
| 7101552 | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same. ... | 09/05/2006 |
| 7097971 | HIV-1 peptide, antigen, immunogenic composition, diagnostic method and immunoassay kit The present invention comprises novel and modified peptides capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are ba... | 08/29/2006 |
| 7098303 | Conserved motif of hepatitis C virus E2/NS1 region Immunogenic polypeptides comprising hepatitis C virus (HCV) immunogens are described. The HCV immunogen comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-P he-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SE... | 08/29/2006 |
| 7094408 | Immunogenicity using a combination of DNA and vaccinia virus vector vaccines This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immu... | 08/22/2006 |
| 7090848 | HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragm... | 08/15/2006 |
| 7067247 | Hepatitis B virus surface protein We isolated and characterized a new surface mutant of the hepatitis B virus surface antigen (HBsAg). The mutant was isolated from a symptomatic patient with Down's syndrome who was found to be persistently positive for both for HBsAg and anti-HBs Antibody (Ab) with ... | 06/27/2006 |
| 7060283 | Immunoreactive peptides from Epstein-Barr virus Epstein-Barr virus (EBV) specific polypeptides consisting of a series of one to 1000 peptide units selected from the group consisting of peptide units Φ, Γ, Δ and Ω, wherein Φ is 25 amino acids or less and has the formula (αETFTETWNRFITHTEβ) (SEQ ID NO:1), Γ... | 06/13/2006 |
| 7052699 | Immunogenic composition The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine. ... | 05/30/2006 |
| 7033593 | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide The invention relates to an immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on the protein, and bound to an HR-2 peptide. The invention also relates to a method o... | 04/25/2006 |
| 7022326 | Carboxymethylated retroviral regulatory proteins and interferon-α This invention relates to retroviral regulatory proteins or fragments thereof, or interferon alpha protein or fragments thereof, which are carboxymethylated. This chemical modification leads to new proteins or fragments which are biologically inactive but preserve t... | 04/04/2006 |
| 7018633 | Selective destruction of cells infected with human immunodeficiency virus Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a varient of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of ... | 03/28/2006 |
| 6974574 | Methods of inducing an HIV specific response using a Vpr-specific epitope The invention features an immunogenic composition containing a frequently-recognized epitope of an HIV-1 accessory protein such as Vpr and methods of inducing an immune response using such an epitope. The epitope peptide contains the amino acid sequence ALIRILQQL of... | 12/13/2005 |
| 6974700 | Kit for use in predicting refractory periodontal disease A kit and method of predicting a refractory response in a subject diagnosed as having periodontal disease by measuring serum concentrations of actinomyces antibodies, streptococcal antibodies and lysine decarboxylase antibodies and using the measurement along with o... | 12/13/2005 |
| 6932972 | Combined vaccine compositions Novel combined vaccine composition preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen... | 08/23/2005 |
| 6911527 | HIV related peptides This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS. ... | 06/28/2005 |
| 6887977 | Methods and materials relating to CD8-tropic HIV-1 The present invention relates to human immunodeficiency viruses 1 (HIV-1) that infect CD8-positive cells using CD8 as a receptor, to detection methods for the viruses and to prophylactic and therapeutic methods for infection by the viruses. ... | 05/03/2005 |
| 6881821 | Hepatitis-C virus type 4, 5, and 6 Newly elucidated sequences of hepatitis C virus type 4 and type 5 are described, together with those of a newly discovered type 6. Unique type-specific sequences in the NS4, NS5 and core regions enable HCV detection and genotyping into types 1 to 6. Antigenic peptid... | 04/19/2005 |
| 6861253 | Polypeptide inducing antibodies neutralizing HIV The present invention thus provides a polypeptide capable of forming a structure corresponding to or mimicking the intermediate of gp41 as well as its use in a vaccine for treating or preventing HIV infections. ... | 03/01/2005 |
| 6855321 | Polyepitope carrier protein The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. The... | 02/15/2005 |
| 6843991 | Use of the M3 protein of MHV68 to block binding of a chemokine to its receptor A pharmaceutical composition comprises M3 protein as encoded by virus MHV 68, or a homologue of said M3 protein, for use in binding to a chemokine or a chemokine analogue in vivo, or to block binding of chemokines to corresponding cell surface receptors in vivo, to ... | 01/18/2005 |
| 6749856 | Mucosal cytotoxic T lymphocyte responses The invention provides methods for induction of an antigen-specific, mucosal cytotoxic T lymphocyte response useful in preventing and treating infections with pathogens that gain entry via a mucosal surface. ... | 06/15/2004 |
| 6705556 | Composition and method for inducing tolerance to viral infection in aquatic animals The White Spot Syndrome Virus (WSSV) is a virus affecting shrimps as well as other crustaceans, and the WSSV epidemic poses a serious threat to the shrimp farming industry. The present invention relates to compositions and methods for inducing tolerance and/or immun... | 03/16/2004 |
| 6692907 | Conserved motif of hepatitis C virus E2/NS1 region The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered... | 02/17/2004 |
| 6692752 | Methods of treating human females susceptible to HSV infection A method of administering a vaccine to females to prevent or treat infections associated with pathogens which cause sexually transmitted diseases is described. The vaccine comprises one or more antigens for the prevention or treatment of sexually transmit... | 02/17/2004 |
| 6689368 | Immunodominant human T-cell epitopes of hepatitis C virus The present invention relates to a polypeptide of about 8 to about 100 amino acids comprising or consisting of at least 8 contiguous amino acids selected from the core, and/or the NS3 regions of the HCV polyprotein, with said contiguous amino acids contai... | 02/10/2004 |
| 6670466 | Human endogenous retrovirus in breast cancer The present invention is related to mammary tumor virus (MTV). MTV represents a group of retroviruses which possess very high homology to mouse mammary tumor virus (MMTV), a virus known to cause neoplastic mammary disease in mice. As described herein, MTV... | 12/30/2003 |
| 6660514 | Method of preparing recombinant adeno-associated virus compositions Disclosed are methods for the isolation and purification of high-titer recombinant adeno-associated virus (rAAV) compositions. Also disclosed are methods for reducing or eliminating the concentration of helper adenovirus in rAAV samples. Methods are discl... | 12/09/2003 |
